A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors - Concepedia

Concepedia

Publication | Open Access

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

DOI Full Paper Access

102

Citations

17

References

2013

Year

Clifford A. Hudis, Charles Swanton, Yelena Y. Janjigian, Ray Lee, Stephanie Sutherland, Robert Lehman, Sarat Chandarlapaty, Nicola Hamilton, Devika Gajria, James Knowles,

Breast Cancer Research

References

	Year	Citations

Page 1